| 货号: S218066 |
| 产品全名: ARL17A/ARL17B 兔多抗 |
| 基因符号 ARF1P2; ARL17P1; ARL17; ARL17A |
| UNIPROT ID: Q8IVW1 (Gene Accession – BC030570 ) |
| 背景: ARL17 (ADP-ribosylation factor-like protein 17), also known as ARF1P2 or ARL17P1, is a 177 amino acid member of the ARF protein family. In human, there are two genes which have been identified as ARL17A and ARL17B that code for identical proteins and colocalize at chromosomal position 17q21.31. ARL17 functions as an activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Localized to the Golgi apparatus, ARL17 may also be involved in the modulation of vesicle budding and uncoating within the Golgi. ARL17 is expressed as three isoforms produced by alternative splicing events.GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking; may modulate vesicle budding and uncoating within the Golgi apparatus (By similarity). |
| 抗原: Fusion protein of human ARL17A/ARL17B |
| 经过测试的应用: ELISA, IHC |
| 推荐稀释比: IHC: 25-100; ELISA: 2000-5000 |
| 种属反应性: Rabbit |
| 克隆性： Rabbit Polyclonal |
| 亚型: Immunogen-specific rabbit IgG |
| 纯化: Antigen affinity purification |
| 种属反应性: Human |
| 成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol |
| 研究领域: Signal Transduction |
| 储存和运输: Store at -20°C. Avoid repeated freezing and thawing |
Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 218066(ARL17A/ARL17B Antibody) at a dilution of 1/20(Cytoplasm and Nucleus). | 
In comparision with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the fusion protein and then with 218066(Anti-ARL17A/ARL17B Antibody) at dilution 1/20. | 
The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using 218066(Anti-ARL17A/ARL17B Antibody) at a dilution of 1/20. | 
In comparision with the IHC on the left, the same paraffin-embedded Human brain tissue is first treated with fusion protein and then with D223646(Anti-ARL17A/ARL17B Antibody) at dilution 1/20. |
|
